Ursprung des Netzwerks ersten Grades von Markus Rüegg
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Neurotune AG
 Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Markus Rüegg
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AC IMMUNE SA | Pharmaceuticals: Major | Chief Operating Officer | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal | |
| University of Groningen | College/University | Doctorate Degree | |
| University of Zurich | College/University | Doctorate Degree Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
Institut Straumann AG
 Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Medical/Nursing Services | Director of Finance/CFO | |
| International Institute for Management Development | College/University | Masters Business Admin | |
| SPEXIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Founder | |
Qvanteq AG
 Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Biotechnology | Founder | |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer |
Statistik
International
| Schweiz | 11 |
| Vereinigte Staaten | 2 |
| Niederlande | 2 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 6 |
| Health Services | 2 |
Operativ
| Corporate Officer/Principal | 5 |
| Chairman | 4 |
| Founder | 4 |
| Doctorate Degree | 3 |
| Chief Executive Officer | 3 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Armin W. Mäder | 7 |
| Bruno Oesch | 6 |
| Jan Willem Vrijbloed | 4 |
| Cornel Sieber | 1 |
- Börse
- Insiders
- Markus Rüegg
- Unternehmensverbindungen
